Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines

被引:0
作者
Nagarjun, B. R. [1 ]
Parikh, Biren [1 ]
Patel, Manaswi Nareshkumar [2 ]
Trivedi, Pina J. [3 ]
Patel, Dharmesh M. [3 ]
机构
[1] Gujarat Canc Res Inst, Dept Oncopathol, GCRI New Bldg,1st Floor,Histopathol Sect,B-105, Ahmadabad 380016, Gujarat, India
[2] Gujarat Canc Res Inst, Former Fellow Oncopathol, Ahmadabad, Gujarat, India
[3] Gujarat Canc Res Inst, Dept Cytogenet, Ahmadabad, Gujarat, India
关键词
ASCO/CAP guidelines 2018; equivocal; FISH; HER2; invasive breast cancer; AMERICAN-SOCIETY; CLINICAL ONCOLOGY/COLLEGE; GENE STATUS; RECOMMENDATIONS; IMPACT;
D O I
10.1055/s-0042-1751052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the management of the patients diagnosed with invasive breast cancer (IBC). It is crucial to identify the patients who truly respond to anti-HER2 targeted therapy. Updated 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines has recommended certain modifications in HER2 interpretation by fluorescence in situ hybridization (FISH) with concomitant immunohistochemistry (IHC). Objectives We aimed to evaluate HER2 FISH interpretation in IBC with equivocal IHC results as per 2018 ASCO/CAP recommendations and compare FISH results with hormonal receptor status. Materials and Methods FISH results of 502 cases of IBC with equivocal IHC report between January 2016 to January 2022 were reviewed retrospectively. FISH results were categorized according to ASCO/CAP guidelines 2018 into five respective groups. Results FISH testing in IHC equivocal cases showed 219 (43.6%) cases were classic amplified (positive) belonged to group 1, 217(43.2%) cases were classic nonamplified (negative) fell into group 5, 39 (7.8%) and 02 (0.4%) patients were in group 2 (negative) and group 3 (positive), and 25 (5.0%) cases were in group 4 (negative). About 52.1 and 49.3% of cases with estrogen receptor and progesterone receptor positivity were reported as HER2 positive. Among 502 cases, 25 equivocal cases according to the 2013 guidelines were redefined as HER2 negative and 02 (0.4%) cases reported positive were classified negative as per updated 2018 guidelines. Conclusion Revised 2018 guidelines is helpful in accurate identification of HER2 status and in avoiding targeted therapy in unwarranted cases. Updated 2018 guidelines has removed equivocal HER2-FISH category that has eliminated management dilemma in these cases. Only long-term clinical follow-up will establish the validity of the updated guidelines.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 23 条
[1]   Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment [J].
Adamczyk, Agnieszka ;
Kruczak, Anna ;
Harazin-Lechowska, Agnieszka ;
Ambicka, Aleksandra ;
Grela-Wojewoda, Aleksandra ;
Domagala-Haduch, Malgorzata ;
Janecka-Widla, Anna ;
Majchrzyk, Kaja ;
Cichocka, Anna ;
Rys, Janusz ;
Niemiec, Joanna .
ONCOTARGETS AND THERAPY, 2018, 11 :4525-4534
[2]   HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation [J].
Ahn, Soomin ;
Woo, Ji Won ;
Lee, Kyoungyul ;
Park, So Yeon .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2020, 54 (01) :34-44
[3]   'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study [J].
Ballard, Morgan ;
Jalikis, Florencia ;
Krings, Gregor ;
Schmidt, Rodney A. ;
Chen, Yunn-Yi ;
Rendi, Mara H. ;
Dintzis, Suzanne M. ;
Jensen, Kristin C. ;
West, Robert B. ;
Sibley, Richard K. ;
Troxell, Megan L. ;
Allison, Kimberly H. .
MODERN PATHOLOGY, 2017, 30 (02) :227-235
[4]   HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity [J].
Hanna, Wedad M. ;
Rueschoff, Josef ;
Bilous, Michael ;
Coudry, Renata A. ;
Dowsett, Mitch ;
Osamura, Robert Y. ;
Penault-Llorca, Frederique ;
van de Vijver, Marc ;
Viale, Giuseppe .
MODERN PATHOLOGY, 2014, 27 (01) :4-18
[5]   Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline [J].
Kong, Hui ;
Bai, Qianming ;
Li, Anqi ;
Zhou, Xiaoyan ;
Yang, Wentao .
DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
[6]  
Lin L, 2019, AM J CLIN PATHOL, V152, P479, DOI [10.1093/AJCP/AQZ061, 10.1093/ajcp/aqz061]
[7]   Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases [J].
Liu, Zhi-Hua ;
Wang, Kun ;
Lin, Dan-Yi ;
Xu, Jie ;
Chen, Jie ;
Long, Xiao-Yu ;
Ge, Yan ;
Luo, Xin-Lan ;
Zhang, Ke-Ping ;
Liu, Yan-Hui ;
Xu, Fang-Ping .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) :51-57
[8]   The New Equivocal Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines [J].
Long, Thomas H. ;
Lawce, Helen ;
Durum, Connie ;
Moore, Stephen R. ;
Olson, Susan B. ;
Gatter, Ken ;
Troxell, Megan L. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (02) :253-262
[9]   Epidemiology of breast cancer in Indian women [J].
Malvia, Shreshtha ;
Bagadi, Sarangadhara Appalaraju ;
Dubey, Uma S. ;
Saxena, Sunita .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) :289-295
[10]   FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma [J].
Okaly, Geeta Vikram Patil ;
Panwar, Dipti ;
Lingappa, Kavitha Bidadli ;
Kumari, Prasanna ;
Anand, Abhishek ;
Kumar, Prashantha ;
Chikkalingaiah, Manju Hosur ;
Kumar, Rekha Vijay .
INDIAN JOURNAL OF CANCER, 2019, 56 (02) :119-123